Metagenomi to Present Preclinical APOC3 Data at Nature Conference
ByAinvest
Monday, Dec 1, 2025 7:02 am ET1min read
IONS--
MGX--
Metagenomi will present preclinical data at the Nature Conference "Cracking the Code: Nucleic Acid Medicines Coming of Age" supporting its collaboration with Ionis Pharmaceuticals on APOC3, a new target for treating severe hypertriglyceridemia. The data will be presented by Alan Brooks, PhD, Senior Vice President of Research at Metagenomi, on December 8, 2025, at 2:45 p.m. EST. The presentation will highlight the potential of CRISPR/Cas-mediated APOC3 knockout as a one-time treatment for severe hypertriglyceridemia.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet